ARS Pharmaceuticals, Inc. (SPRY)
5.62
-0.05
(-0.88%)
USD |
NASDAQ |
Sep 04, 16:00
5.62
0.00 (0.00%)
Pre-Market: 20:00
ARS Pharmaceuticals SG&A Expense (TTM) : 284.49M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 284.49M |
| March 31, 2026 | 261.22M |
| December 31, 2025 | 230.12M |
| September 30, 2025 | 205.66M |
| June 30, 2025 | 150.19M |
| March 31, 2025 | 104.82M |
| December 31, 2024 | 71.68M |
| September 30, 2024 | 43.00M |
| June 30, 2024 | 38.70M |
| March 31, 2024 | 43.06M |
| December 31, 2023 | 47.28M |
| September 30, 2023 | 40.46M |
| June 30, 2023 | 28.41M |
| March 31, 2023 | 17.56M |
| Date | Value |
|---|---|
| December 31, 2022 | 7.723M |
| September 30, 2022 | 15.36M |
| June 30, 2022 | 19.47M |
| March 31, 2022 | 23.78M |
| December 31, 2021 | 28.08M |
| September 30, 2021 | 24.71M |
| June 30, 2021 | 17.67M |
| March 31, 2021 | 12.25M |
| December 31, 2020 | 6.429M |
| September 30, 2020 | 2.823M |
| June 30, 2020 | 2.823M |
| March 31, 2020 | 1.486M |
| December 31, 2019 | 0.658M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Passage Bio, Inc. | 20.93M |
| Vertex Pharmaceuticals, Inc. | 2.008B |
| Capricor Therapeutics, Inc. | 35.43M |
| Kyntra Bio, Inc. | 27.67M |
| Zentalis Pharmaceuticals, Inc. | 37.06M |